Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC)

Authors

• William Kelly

Publication/Presentation Date

5-2025

Volume

43

Issue

16

Published In/Presented At

DOI: 10.1200/JCO.2025.43.16_suppl.TPS5118

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article